The polysaccharide capture is a patent pending method (WO2014012168) that is used for the isolation and purification of extracellular vesicles (EV). Species of complex sugars are used for the precipitation and capture of EVs using slow and gentle procedures keeping the integrity of the vesicles for subsequent applications. ACRI’s candidate polysaccharides are already FDA approved for multiple formulations, wound healing and internal use, making them ideal for therapeutic purposes in human medicine. Using stem cell-derived EVs or drug-loaded EVs could show promise in the medical field.
The low cost of the molecules makes this method amenable to large scale isolation of EVs for therapeutic purposes.
What are exosomes and EVs?
Exosomes and extracellular vesicles (EVs) are cell-derived nano-sized membrane-encapsulated particles (30-300nm) that act as intermediates in an elaborate communication network, which cells in the body use to deliver complex messages to other cells. EVs can be viewed as nano-cargo transports that circulate in both humans and animals and contain vital information that can inform us in real-time on both normal and disease processes that are occurring within the body. As such, EVs contain a sample of the DNA, RNA, protein and metabolites found within the cells from which they are derived. Since EVs appear in body fluids such as blood and urine, they are also a biomarker source that may be obtained by minimally-invasive methods in order to screen for disease.
For technology information, collaborations or partnerships, please contact:
Remi Richard
Business Development Agent
This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone : +1 506 869 2048
Fax : +1 506 862 7571
